Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
CAR T cells expressing anti-CD19 and signaling molecules CD28 and CD3-zeta chain induced complete remission in 83% of patients with refractory ALL. Patients with a low disease burden had longer survival and a lower rate of toxic effects than those with a high disease burden.
Alternative Titles
Full title
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6637939
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6637939
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1709919
